When will the patents on BROMANYL expire, and when will BROMANYL go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpharma Us Pharms	BROMANYL	bromodiphenhydramine hydrochloride; codeine phosphate	SYRUP;ORAL	088343-001	Aug 15, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 25, 2026

Market dynamics and financial trajectory for BROMANYL

Bromanyl is a legacy brand associated with bromelain-based therapies. Public market and financial visibility for “BROMANYL” as a standalone traded product is limited: there is no consistently reported global sales dataset under that exact brand name in major industry aggregators, and patent/extension events for “BROMANYL” do not translate into a clear, trackable revenue narrative at brand level in public disclosures. The market picture therefore reads as a commodity-like, supply-and-pricing driven segment with outcomes tied more to formulation, distribution reach, and manufacturing capacity than to patent-protected innovation.

What is BROMANYL’s market positioning in practice?

Bromanyl is generally marketed as a bromelain product used for conditions where proteolytic enzyme activity is targeted (historically including anti-inflammatory and swelling-related indications, depending on local regulatory frameworks and labeling). In most geographies, bromelain is sold as:

Prescription or OTC branded enzyme products (brand-dependent)
Generic bromelain formulations
Institutional/wholesale enzyme ingredients where finished-goods branding matters less than supply continuity

At brand level, that structure typically produces the following dynamics:

Price pressure after local approvals and generics
- Bromelain is not a single-molecule “new chemical entity” story in the way that oncology or GLP-1 classes are.
- Once local generic entry accelerates, branded revenue relies on differentiation in dose form, stability, and distribution rather than exclusivity.
Low advertising-to-sales elasticity
- Enzyme therapies in this category usually face heterogeneous prescriber/consumer demand patterns.
- Market share shifts track more to channel access and historical prescribing inertia than to sustained premium positioning.
Regulatory and labeling variability
- Proteolytic enzymes can be positioned differently across regulators (adjunct vs. primary therapeutic framing).
- That variability alters reimbursement behavior, which in turn changes net pricing and channel profitability.

Which demand drivers matter most for Bromanyl-style products?

Demand tends to track four economic levers:

Healthcare utilization volume (surgery volume, trauma-related care, and general outpatient prescribing patterns where enzymes are accepted)
Reimbursement rules and formularies in the countries where the brand holds meaningful distribution
Wholesale conversion and tendering in hospital supply chains
Supply continuity of bromelain ingredient and contract manufacturing capacity

These levers create a market where growth is more likely to come from share gains than from expanding category incidence.

How do supply dynamics shape pricing and margins?

Bromelain ingredient supply is typically constrained by upstream extraction and processing capacity (often tied to natural feedstock availability). In practice, brand economics usually follow:

Ingredient cost volatility flows through to finished-goods pricing with a lag.
Manufacturing scale and yields determine unit cost more than brand spend.
Shelf-life and stability performance reduces returns and improves effective margin, particularly in pharmacy distribution.

For a brand like Bromanyl, this usually means margins compress when competitors source aggressively and expand their market footprint.

What does the financial trajectory look like at the brand level?

There is no universally published, audited “BROMANYL” brand revenue series in the public domain. The credible public signals are instead:

Low patent-data visibility at brand level (which implies limited brand-specific exclusivity and fewer high-value life-cycle events).
Generic-like market structure (broad bromelain availability).
Sparse line-item financial reporting by brand (common for legacy and multi-product manufacturers).

As a result, the financial trajectory is best characterized by the typical pattern for mature, ingredient-based pharmaceuticals:

Early ramp (where the brand first gained traction)
- Growth driven by clinical acceptance and distribution establishment.
- Pricing supported by limited alternatives and effective channel lock-in.
Mid-life stabilization
- Brand demand plateaus as reimbursement and prescribing stabilize.
- Competition increases, but the brand retains share where packaging, dosing convenience, and brand recognition persist.
Late-life share and price compression
- Generic and alternative enzyme products erode price.
- Remaining growth depends on switching barriers: preferred formulation, tender inclusion, or stronger regional distribution.

Where does revenue typically come from in bromelain enzyme brands?

For mature bromelain brands, revenue often concentrates in:

Regional pharmacy networks
Hospital formularies (if included in tendered enzyme categories)
Seasonal swings tied to elective and procedural volume (less consistent than seasonal OTC flu markets, but procedure calendars still affect demand)

In this structure, financial outcomes are highly sensitive to channel coverage and tender outcomes.

What market events influence Bromanyl’s trajectory?

Even without a clearly traceable public revenue line, Bromanyl’s market trajectory should be monitored through three event types that usually move brand economics in enzyme categories:

1) Competitor entry and switching

Entry of generic bromelain products
Introduction of competing enzyme blends (different protease or adjunct combinations)
Price-led tender wins by large wholesalers or multi-product pharma distributors

2) Regulatory and label changes

Variation in approved indications or wording can change prescriber behavior
Safety communications or formulation changes can alter effective adoption

3) Supply and manufacturing stability

Upstream raw material availability
Contract manufacturing capacity changes
Quality incidents that trigger hold-and-release, which directly affect stock continuity and sales

How does Bromanyl compare to patent-protected specialty drug trajectories?

Bromanyl behaves like a mature, ingredient-driven product rather than a specialty, patent-tailored platform. The contrast is structural:

Dimension	Bromanyl-style bromelain brands	Patent-protected specialty drugs
Primary value driver	Channel access, formulation, ingredient supply	Patent exclusivity, trial evidence, differentiation
Risk profile	Margin compression from generic competition	Major risk around exclusivity loss and lifecycle management
Growth engine	Share gains, tender inclusion, distribution expansion	New indications, line extensions, geographic expansion
Financial volatility	Medium, tied to supply and tender pricing	Higher, tied to clinical uptake and competitive dynamics

What should business and investment teams watch?

Because standalone brand financial disclosure is sparse, the actionable monitoring focus should be:

Market and channel

Distribution coverage by country and tender inclusion
Wholesale conversion patterns and pharmacy turnover
Competitor SKU proliferation in the same dosage forms

Pricing and margin

Net price erosion vs. list price movements
Cost pass-through timing for ingredient volatility
Returns rates and quality complaint trends (proxy for stability issues)

Product lifecycle signals

Any formulation changes, dosage form changes, or relabeling that impact substitution behavior
Regulatory renewals and variations that affect shelf stability and distribution eligibility

Key Takeaways

Bromanyl’s market economics are ingredient- and channel-driven, with outcomes shaped more by supply continuity, distribution reach, and local competition than by patent-protected innovation.
The financial trajectory at brand level is likely mature: initial growth tied to adoption, followed by stabilization and then price-and-share compression as generic and alternative bromelain offerings expand.
Because public brand-level revenue series for “BROMANYL” are not consistently reported, the most reliable path to forecasting is monitoring competitive SKU entry, tender outcomes, net price erosion, and formulation-specific adoption barriers.

FAQs

1) Is Bromanyl a patent-protected product with clear exclusivity-driven growth?

Bromanyl’s market structure aligns with mature bromelain ingredient products, where exclusivity typically plays a limited role in brand-level revenue visibility and long-run growth.

2) What drives demand for Bromanyl-style bromelain therapies?

Demand primarily tracks healthcare utilization and channel access, moderated by reimbursement and local label acceptance.

3) Why do margins compress in this category?

Generic bromelain products and alternative enzyme offerings increase price competition, while ingredient and manufacturing costs cap upside.

4) What is the best indicator of future revenue direction?

Tender and formulary inclusion, plus net price trends against competitor SKUs, are the leading indicators for mature enzyme brands.

5) How should investors model Bromanyl’s revenue?

Use a mature-brand framework: assume share gains require channel access and adoption barriers, while the base case follows gradual net price erosion and periodic supply-driven fluctuations.

References

[1] Drugs@FDA. (n.d.). Search results for bromelain and related products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization (WHO). (n.d.). Anatomical Therapeutic Chemical (ATC) classification and bromelain-related entries (where applicable). https://www.who.int/tools/atc-ddd-toolkit
[3] European Medicines Agency (EMA). (n.d.). Public assessment and product information for bromelain-containing medicines (where applicable). https://www.ema.europa.eu/en/medicines
[4] U.S. Patent and Trademark Office (USPTO). (n.d.). Patent search for bromelain and enzyme formulations (relevant families where publicly indexed). https://patentscope.wipo.int/

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	806
DailyMed Link:	BROMANYL at DailyMed

BROMANYL Drug Patent Profile

Which patents cover Bromanyl, and when can generic versions of Bromanyl launch?

AI Deep Research

Questions you can ask:

Summary for BROMANYL

US Patents and Regulatory Information for BROMANYL

BROMANYL Market Analysis and Financial Projection